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Abstract
Summary Patients with inflammatory bowel disease (IBD)
are at risk of osteoporosis. Vitamin D (vitD) deficiency is
known as a risk factor of osteoporosis. We observed low
vitD blood levels in adult IBD patients both at the end of
summer and winter. Furthermore, effects of oral vitD
supplementation in (generally low) daily dosages were
poor.
Introduction Patients with IBD are at risk of osteoporosis.
This study evaluates seasonal vitD status, determinants of
vitD deficiency and effects of vitD supplementation in adult
IBD patients.
Methods Patients were screened for vitD deficiency at the
end of summer and winter using serum 25OHD3 (cut-off
point, <50 nmol/L) combined with routine laboratory tests.
A standardized questionnaire was used for demographic/
lifestyle data i.e. IBD activity, health behaviour and vitD
intake through diet and ultraviolet light.
Results Late-summer, 39% of the included 316 patients were
vitD deficient. Late-winter, 57% of the follow-up patients (n=
281) were deficient. Independent protective determinants of
vitD deficiency were oral vitD supplementation (summer/
winter: odds ratio [OR], 0.52 [95% confidence interval [CI],
0.29–0.94]/OR, 0.44 [95% CI, 0.26–0.75]), recent sun
holiday (summer: OR, 0.42 [95% CI, 0.24–0.74]) and
regular solarium visits (summer/winter: OR, 0.28 [95% CI,
0.13–0.63]/OR, 0.17 [0.06–0.50]). IBD activity (p=0.031),
red blood cell distribution width (RDW; p=0.04) and
erythrocyte sedimentation rate (p=0.03) were associated
with low vitD levels using univariate analyses of the extreme
25OHD quartiles. In a subgroup with vitD supplementation,
still 30% (late-summer) and 44% (late-winter) were vitD
deficient.
Conclusion VitD deficiency is common in IBD patients,
but prevalence might be comparable with the general
population. Ultraviolet light is essential for adequate vitD
levels. Effects of oral vitD supplementation in (generally
low) daily dosages are poor. Determinants for low vitD
levels were IBD activity and elevated inflammatory
markers, suggesting that increased risk of osteoporosis in
IBD might be more related to the inflammation than to vitD
deficiency.
Keywords Inflammatory bowel disease . Osteoporosis .
Pathophysiology . Prevalence . Seasonal variation . Serum
25-hydroxyvitamin D
Introduction
Patients with Crohn’s disease (CD) and ulcerative colitis
(UC), the two most common forms of inflammatory bowel
disease (IBD), have an increased risk of developing
osteoporosis [1, 2]. Osteoporosis is characterized by a low
bone mineral density and deteriorated micro-architecture of
the skeleton, which leads to increased fracture risks [3]. The
pathophysiology of IBD-related osteoporosis is presumably
multifactorial and up to now not fully understood [3, 4].
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Different pathways can be distinguished including the
negative effects of glucocorticoid therapy, malnutrition
leading to low body weight, systemic effects of chronic
inflammatory reactions through pro-inflammatory cytokines
and vitamin D deficiency.
Vitamin D deficiency is known as an important risk factor
of osteoporosis in the general population and leads to
increased bone resorption caused by secondary hyperparathy-
roidism [5]. Available literature concerning vitamin D
deficiency and the seasonal variation of 25OHD levels in
IBD is limited. Some authors reported high prevalence rates
of vitamin D deficiency in IBD patients, especially in CD,
but these conclusions are based on relatively small sample
sizes [6–10]. To our knowledge, little information is
currently available on seasonal variation of vitamin D levels
in both CD and UC patients.
In this prospective cohort study, we analysed the vitamin D
status both at the end of the summer and winter period in adult
IBD patients attending our gastroenterology department.
Additionally, we investigated potential determinants of




Patients aged 18 years or older and diagnosed with IBD
who attended our gastroenterology department in the last
2 years (n=459) were invited by mail to participate in this
project. The diagnosis of IBD had to be confirmed on
clinical grounds, with endoscopic and/or radiologic
evidence, supported by histological mucosal findings
according to the Lennard–Jones criteria [11]. Patients
diagnosed with ‘indeterminate colitis’ were excluded from
this study. All included patients were screened for vitamin
D deficiency at the end of summer 2009 (September–
November) and winter 2009–2010 (January–March) at the
gastroenterology outpatient department of a large teaching
hospital in the centre of the Netherlands. Written informed
consent was obtained from all participants. The study
protocol was approved by the local Medical Ethics
Committee of the Meander Medical Centre.
Data collection
A standardized questionnaire was used to analyse informa-
tion on self-reported demographic data i.e. age, sex,
ethnicity, health behaviour, physical activity, current smok-
ing and alcohol usage. Physical activity was assessed using
the SQUASH (Short QUestionnaire to ASess Health)
questionnaire according to the national physical activity
scale [12]. Excessive alcohol usage was defined as >21
alcoholic units per week for men and >14 alcoholic units
per week for women. Disease activity of IBD was assessed
by the Manitoba IBD index [13]. This index is based on
patient self-reports enclosing IBD-related symptoms in the
last 6 months. Other patient characteristics were retrieved
from documented medical records in order to obtain data of
fractures in the past and corticosteroid usage. Body mass
index was measured by calculating weight in kilograms
divided by the square height in meters. For their vitamin D
assessment, patients had to undergo serum 25OHD mea-
surement at the end of summer and winter and complete
two questionnaires. In these questionnaires, patients were
asked to report their daily oral vitamin D supplementation
(including daily dosages and type of supplementation i.e.
prescription medication and/or over the counter supple-
ments), medication compliance, preferred exposure to
sunlight or shade when outdoors and average number of
days per week with >2 midday hours exposure to sunlight
during summer. Furthermore, sun holidays in the last
6 months, frequency of solarium visits, calcium intake
(dairy products /day) and intake of fatty fish (servings/
month), i.e. mackerel, herring and salmon, were assessed.
Laboratory measurements
Original serum samples were drawn in EDTA, respectively,
heparin-containing collection tubes, centrifuged and stored
at −30°C. Biochemical and haematological laboratory
markers (e.g. haemoglobin (Hb), haematocrit (Ht), red blood
cell distribution width (RDW), erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), calcium, phosphate, alkaline
phosphatase, albumin, creatinine and thyroid stimulating
hormone) were measured at the end of summer (September–
November 2009). Serum 25OHD3 levels were analysed as
indicator of the vitamin D status at the end of the summer
(September–November 2009) and winter period (January–
March 2010) using an electrochemiluminescence immuno-
assay (ECLIA) from Roche on a Cobas E module (Roche
Diagnostics®, Penzberg, Germany). The between-run CV
was 4.6% at 53 nmol/L and 9.9% at 28 nmol/L. We defined
25OHD3 levels <50 nmol/L (20 ng/mL) as being vitamin D
deficient.
Statistical analyses
Statistical analyses were performed using SPSS 17.0
(SPSS Inc., Chicago, IL, USA). For univariate compar-
ison, 25OHD levels were stratified in two groups
(vitamin D deficiency, <50 nmol/L, and adequate vitamin
D status, ≥50 nmol/L). Univariate statistical analyses
were performed by using a parametric test (unpaired t
test) when a normal distribution was present and, when in
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order, a non-parametric test (Mann–Whitney U) to assess
significant associations between the stated continuous
determinants and the various groups (CD patients vs. UC
patients, and vitamin D deficiency vs. adequacy). Cate-
gorical determinants were analysed by using Pearson’s
Chi-square test (or Fisher’s exact test when expected
frequencies were low). Furthermore, quartiles according
the 25OHD levels were stratified and assessed using a
one-way ANOVA test with a Bonferroni post hoc test as
parametric test when a normal distribution was present,
and a non-parametric test (Kruskal–Wallis test) when in
order to assess significant associations between the stated
determinants and 25OHD quartiles. Mean differences
between 25OHD levels in summer and winter were
calculated with the non-parametric Wilcoxon signed rank
test. In order to identify independent risk factors of
vitamin D deficiency in summer and winter, a logistic
regression model was used with vitamin D deficiency as
dependent factor. All p values >0.10 are noted in the tables
as NS (non-significant). All p values between 0.5 and 0.10
are noted in order to identify non-significant trends. All p
values <0.05 were considered as statistically significant.
Results
In this study, 316 patients with a mean age (±SD) of
48.5±14.8 years were included (Table 1). Fifty-seven
percent of the included patients were women. Ninety-
seven percent of the patients were of Caucasian ethnicity.
The main group of IBD patients was diagnosed with UC
(59%). The mean duration of IBD (±SD) was 11.0 ±
9.7 years.
Vitamin D deficiency in summer and winter
At the end of summer, vitamin D deficiency was seen in
39% (95% confidence interval [CI], 33.3–44.2) of the
included IBD patients with a mean serum 25OHD level of
55.1 nmol/L (Tables 2 and 3). Univariate analysis of
vitamin D deficiency at the end of summer using
50 nmol/L as cut-off point resulted in the following
significant predictors. Associations were found between
an adequate vitamin D status and daily oral vitamin D
supplementation (p = 0.029), smoking (p = 0.005),
preferred sun exposure when outdoors (p = 0.020), regular
solarium visits (p = 0.003) and sun holiday (p < 0.001).
Predictive factors for vitamin D deficiency were high body
mass index (p = 0.002) and the elevated biochemical
marker alkaline phosphatase (p = 0.003). Late-summer,
non-significant trends were found between vitamin D
adequacy and the UC (p = 0.08), female gender (p =
0.07) and the haematological marker RDW (p = 0.06).
In the follow-up measurement at the end of winter,
serum 25OHD levels of 281 patients (loss to follow-up, n =
35) were determined. In this follow-up group, 57% of the
patients were vitamin D deficient with a mean serum
25OHD of 48.8 nmol/L. The mean difference (CI) of
25OHD levels between summer and winter was 7.4 nmol/L
(5.54–9.26 nmol/L), and 25OHD levels differed signifi-
cantly between these two periods (p < 0.001) in our study
population. Univariate analysis resulted in three significant
determinants reducing the risk of vitamin D deficiency at
the end of winter: oral vitamin D supplementation usage
during winter (p < 0.001), sun holiday during winter (p =
0.047) and regular solarium visits during winter (p =
0.012). At the end of summer and winter, no significant
univariate associations were found between low serum
vitamin D levels and age, gender, type of IBD (CD vs. UC),
alcohol usage, disease duration and physical activity.
Vitamin D quartiles
By using univariate analyses of the vitamin D quartiles,
several significant associations have been observed (Table 4).
High body mass index (p = 0.010) and elevated blood levels
of alkaline phosphatase (p = 0.022) were associated with
low vitamin D levels. Preferred exposure to sun when
outdoors (p = 0.003), sun holiday (p < 0.001), solarium
visits (p = 0.020) and current smoking (p = 0.009) were
associated with high vitamin D levels. Non-significant trends
were observed between high vitamin D levels and daily oral
vitamin D supplementation usage (p = 0.07), sufficient
physical activity (p=0.06) and elevated creatinine levels (p =
0.08). Low vitamin D levels were non-significantly associ-
ated with increased fatty fish intake (p = 0.05). Furthermore,
comparison of the lowest and highest quartile of vitamin D
levels (serum 25OHD, <42 vs. ≥67 nmol/L) led to the
significant associations between low vitamin D levels and
disease activity of IBD (p = 0.031) and elevated blood levels
of RDW (p = 0.04) and ESR (p = 0.03).
Multivariate analyses
By using a logistic multivariate regression model, indepen-
dent risk factors of vitamin D deficiency could be identified
(Table 5). Based on the late-summer measurements, UC
(odds ratio [OR], 0.55 [95% CI, 0.31–0.95]), current
smoking (OR, 0.27 [0.13–0.57]), oral vitamin D supple-
mentation (OR, 0.52 [0.29–0.94]), recent sun holiday (OR,
0.42 [0.24–0.74]) and regular solarium visits (OR, 0.28
[0.13–0.63]) independently decreased the risk of being
vitamin D deficient. Furthermore, high body mass index
(OR, 1.11 [95% CI, 1.05–1.19]) independently increased
the risk of vitamin D deficiency. During winter, oral
vitamin D supplementation (OR, 0.44 [0.26–0.75]) and
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regular solarium visits (OR, 0.17 [0.06–0.50]) were
associated with a decreased risk of being vitamin D
deficient.
Vitamin D supplementation
In this study population, 106 patients (34%) used daily oral
vitamin D supplementation (vitamin D3: cholecalciferol)
during summer with a mean daily dosage of 7.6 μg (334
international units [IU]) ranging between 1.3 (57 IU) and
40 μg (17.600 IU). Nevertheless, 27% of the patients with
supplementation were still vitamin D deficient at the end of
summer. During winter, 117 patients (43% of n = 281) used
oral vitamin D supplements with a mean daily dosage of
9.5 μg (418 IU). In this follow-up group, still 53 patients
(45%) with vitamin D supplementation were vitamin D
deficient. Patients who used oral vitamin D supplementa-
tion in combination with additional ultraviolet light expo-
sure (through sun holidays or solarium visits) had mean
serum 25OHD levels of 61.3 nmol/L at the end of summer
and 55.7 nmol/L at the end of winter. Patients without any
additional vitamin D intake through oral supplementation
Table 1 Baseline characteristics and laboratory results of IBD patients
Total CD patients UC patients p valuea
n=316 n=131 n=185
Age, years (SD) 48.5 (14.8) 46.5 (14.7) 49.9 (14.8) 0.046
Women, n (%) 181 (57.3) 84 (64.1) 97 (52.4) 0.039
Postmenopausal state, n (% of women) 71 (39.2) 32 (38.1) 39 (40.2) NS
Body mass index, kg/m2 (SD) 25.3 (4.5) 25.5 (4.8) 25.1 (4.3) NS
Active IBD, n (%) 160 (50.6) 70 (53.4) 90 (48.6) NS
Disease duration IBD, years (SD) 11.0 (9.7) 11.1 (10.0) 11.0 (9.6) NS
Exacerbation IBD, episodes/year (SD) 2.7 (2.1) 2.8 (2.2) 2.7 (1.9) NS
History of >7.5 mg daily corticosteroid usage for at least 6 months, n (%) 92 (29.1) 38 (29.0) 54 (29.2) NS
Daily use of oral vitamin D supplementation, n (%) 106 (33.5) 42 (32.1) 64 (34.6) NS
Low dietary calcium intake, n (%) 15 (4.8) 6 (4.6) 9 (4.9) NS
Fatty fish intake, units/month (SD) 2.6 (2.5) 2.6 (2.3) 2.7 (2.5) NS
Excessive alcohol usage, n (%) 34 (10.9) 11 (8.5) 23 (12.6) NS
Current smoking, n (%) 73 (23.1) 46 (35.1) 27 (14.6) <0.001
Preferred exposure to sun when outdoors, n (%) 166 (53.7) 61 (36.7) 105 (63.3) 0.041
Outdoor activities at least 2 h a day
Summer, days/week (SD) 4.5 (2.1) 5.4 (2.1) 5.4 (2.1) NS
Winter, days/week (SD) 3.0 (2.5) 3.1 (2.5) 2.9 (2.4) NS
Sun holiday in the last year, n (%) 138 (44.5) 49 (37.7) 89 (49.4) 0.040
Solarium visits, n (%) 64 (20.6) 27 (20.8) 37 (20.6) NS
Laboratory markers in serum
Hb, mmol/L (SD) 8.6 (0.92) 8.5 (0.90) 8.7 (0.93) NS
Ht, L/L (SD) 0.41 (0.04) 0.40 (0.04) 0.41 (0.04) NS
RDW, % (SD) 44.6 (4.8) 45.8 (5.2) 43.7 (4.2) <0.001
ESR, mm/h (SD) 14.1 (12.7) 15.7 (10.8) 13.0 (13.8) <0.001
CRP, mg/L (SD) 4.5 (7.7) 5.1 (6.4) 4.1 (8.6) <0.001
Calcium, mmol/L (SD) 2.3 (0.1) 2.4 (0.1) 2.3 (0.09) NS
Phosphate, mmol/L (SD) 1.1 (0.2) 1.1 (0.2) 1.1 (0.2) NS
Albumin, g/L (SD) 40.6 (3.2) 40.1 (3.2) 40.9 (3.2) 0.006
Creatinine, μmol/L (SD) 72.9 (15.7) 71.2 (13.7) 74.2 (16.8) NS
TSH, mIU/L (SD) 1.53 (0.87) 1.50 (0.95) 1.54 (0.81) NS
SD standard deviation, Hb haemoglobin, Ht haematocrit, RDW red blood cell distribution width, ESR erythrocyte sedimentation rate, CRP C-
reactive protein, TSH thyroid stimulating hormone
a Statistical analyses between CD and UC patients were performed by using a parametric test (unpaired t test) when a normal distribution was present
and when in order a non-parametric test (Mann–Whitney U) to assess univariate significant associations between the stated continuous determinants and
CD vs. UC. Categorical determinants were analysed by using Pearson’s Chi-square test (or Fisher’s exact test when expected frequencies were low). All
p values >0.10 are noted as NS (non-significant). All p values between 0.5 and 0.10 are noted in order to evaluate non-significant trends associated
between the groups
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or sun exposure had lower mean serum 25OHD levels of
48.4 nmol/L at the end of summer and 42.7 nmol/L at the
end of winter (Fig. 1).
In general, a decreased risk of vitamin D deficiency was
seen in patients who used daily oral vitamin D supplemen-
tation during summer (p = 0.029) and winter (p < 0.001).
Higher dosages of supplementation did not lower the risk of
developing vitamin D deficiency, although a non-
significant negative trend was seen between the daily
dosage of vitamin D supplementation and the risk of being
vitamin D deficient (p = 0.09).
Discussion
This prospective cohort study demonstrates that vitamin D
deficiency, with a prevalence of 39% at the end of summer,
is a common problem in IBD patients. Furthermore, strong
seasonal variation of vitamin D levels was observed, with a
decline of mean serum 25OHD levels from 55.1 nmol/L at
the end of summer to 48.4 nmol/L at the end of winter,
leading to an overall vitamin D deficiency prevalence of
57% in the sun-deprived months. To our knowledge, this is
the largest study up till now which investigates the
seasonality of vitamin D levels in a cohort of adult IBD
outpatients. Our results are in line with the few data
currently available concerning vitamin D deficiency in IBD
patients. McCarthy et al. described in 44 CD patients
prevalence rates of vitamin D deficiency of 18% (cut-off
point, <50 nmol/L) late-summer and 50% late-winter [14].
Kuwabara et al. reported vitamin D deficiency prevalence
rates of even 76% in 70 IBD patients at the end of summer
(cut-off point, <50 nmol/L) [10]. Generally, we can
conclude that our study, which is characterized by a large







Ulcerative colitis, n (%) 64 (52.2) 121 (62.4) 0.08
Age, years (SD) 48.6 (14.7) 48.5 (14.9) NS
Women, n (%) 62 (50.8) 119 (61.3) 0.07
Postmenopausal state, n (% of women) 28 (45.2) 43 (36.1) NS
Body mass index, kg/m2 (SD) 26.5 (5.3) 24.4 (3.7) 0.002
Active IBD, n (%) 67 (54.9) 93 (47.9) NS
Disease duration IBD, years (SD) 11.3 (10.8) 10.9 (9.0) NS
Exacerbation IBD, episodes/year (SD) 2.8 (2.1) 2.7 (2.0) NS
History of >7.5 mg daily corticosteroid usage for at least 6 months, n (%) 42 (34.4) 50 (25.8) NS
Excessive alcohol usage, n (%) 10 (8.4) 24 (12.5) NS
Sufficient physical activity, n (%) 67 (54.9) 93 (47.9) NS
Current smoking, n (%) 17 (13.9) 56 (28.9) 0.005
Preferred exposure to sun when outdoors, n (%) 53 (45.3) 113 (58.9) 0.020
Laboratory markers in serum
Hb, mmol/L (SD) 8.7 (0.9) 8.6 (0.9) NS
Ht, L/L (SD) 0.41 (0.04) 0.41 (0.04) NS
RDW, % (SD) 45.3 (5.6) 44.2 (4.1) 0.06
ESR, mm/h (SD) 14.9 (13.4) 13.7 (12.2) NS
CRP, mg/L (SD) 4.3 (5.7) 4.7 (8.8) NS
Calcium, mmol/L (SD) 2.4 (0.1) 2.4 (0.1) NS
Phosphate, mmol/L (SD) 1.1 (0.2) 1.1 (0.2) NS
Alkaline phosphatase, IU/L (SD) 79.6 (21.9) 75.2 (31.9) 0.003
Albumin, g/L (SD) 40.7 (3.0) 40.5 (3.4) NS
Creatinine, μmol/L (SD) 73.3 (15.5) 72.7 (15.8) NS
TSH, mIU/L (SD) 1.6 (1.0) 1.5 (0.8) NS
a Statistical analyses were performed by using a parametric test (unpaired t test) when a normal distribution was present and when in order a non-parametric
test (Mann–Whitney U) to assess univariate significant associations between the stated continuous determinants and vitamin D deficiency. Categorical
determinants were analysed by using Pearson’s Chi-square test (or Fisher’s exact test when expected frequencies were low). All p values >0.10 are noted as
NS (non-significant). All p values between 0.5 and 0.10 are noted in order to evaluate non-significant trends associated with vitamin D deficiency
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and representative IBD outpatient cohort, confirms the high
prevalence of vitamin D deficiency which was presumed in
preliminary studies.
Prevalence rates of vitamin D deficiency in the general
population are better documented compared to the relative-
ly small subgroup of IBD patients; unfortunately, the
usefulness of these prevalence data for comparison with
our diseased group is limited. In the Netherlands, represen-
tative population-based studies are lacking. Comparison
between studies, specifically between different countries, is
further hampered by differences in study designs, latitude,
age and the lack of international consensus on serum
25OHD cut-off levels [15–17]. Recently, a population-
based survey performed by Hinztpeter et al. in Germany
which included over 4,000 adults reported that 57%
(95% CI, 55.5–58.5) of the participants had serum
25OHD levels <50 nmol/L [18]. In Great Britain, a
population-based study performed by Hyppönen et al.
reported comparable data with a mean 25OHD level of
60.3 nmol/L (95% CI, 59.5–61.0) and 15% (95% CI,
14.4–16.5) of the included 45-year-old participants with
serum 25OHD levels <40 nmol/L [19]. Although we are
aware of the fact that comparison between our study
results and existing evidence is hampered by methodolog-
ical differences, it seems that prevalence rates of vitamin
D deficiency in our study population of Dutch IBD
patients might be comparable with prevalence rates in
the general population of neighbouring countries.
Exposure to ultraviolet light
Seasonal variation of serum 25OHD is caused by the strong
dependence on the exposure to sunlight, especially in
people living at high latitudes. Ultraviolet light stimulates
the conversion of 7-dehydrocholesterol to cholecalciferol
(vitamin D3) in the skin and is therefore essential for
optimal vitamin D levels [20]. With regard to the 25OHD3
half-life of 2 months, the highest annual vitamin D levels in
the northern hemisphere are expected in August/September
and the lowest in February/March [21]. This annual variation
has been observed by Hintzpeter et al. reporting maximum
serum 25OHD levels in September and minimum levels in
March [18]. The important physiologic effects of ultraviolet
light are directly reflected in our results concerning the
determinants for vitamin D deficiency. In summer, ultraviolet
exposure in terms of preferred sun exposure when outdoors
(p = 0.020), regular solarium visits (p = 0.003) and sun
holidays in the last 6 months (p < 0.001) are of importance for
adequate vitamin D levels. During winter, the participants had
to rely on the exposure to ultraviolet light by regular solarium
visits (p < 0.001) or visiting sunny holiday destinations (p =
0.047) to obtain an adequate vitamin D status.
Dietary intake, smoking and body mass index
In the Netherlands, only a few nutritional products (i.e.
fatty fish and margarine) contain vitamin D3 (Dutch dietary
Table 3 Determinants of vitamin D status in IBD patients stratified by season
















n=316 n=122 n=194 n=281 n=160 n=121 Summer Winter
Oral vitamin D
supplementation, n (%)
106 (33.5) 32 (26.6) 74 (38.1) 117 (43.5) 53 (34.6) 64 (55.2) 0.029 <0.001
Fatty fish intake,
units/month (SD)
2.6 (2.5) 2.7 (2.8) 2.5 (2.0) 2.6 (2.2) 2.8 (2.4) 2.5 (2.0) NS NS
Outdoor activities at least
2 h a day, days/week
(SD)
5.4 (2.1) 5.3 (2.1) 5.5 (2.1) 3.0 (2.5) 3.1 (2.5) 2.9 (2.5) NS NS
Recent sun holiday, n (%) 138 (44.5) 39 (33.1) 99 (51.6) 28 (10.1) 11 (7.0) 17 (14.3) <0.001 0.047
Regular solarium
visits, n (%)
64 (20.6) 14 (11.9) 50 (26.0) 28 (10.1) 7 (4.5) 21 (17.6) 0.003 0.012
Serum 25OHD level,
nmol/L (SD)
55.1 (16.4) 39.1 (7.8) 65.1 (11.8) 48.4 (20.0) 35.6 (11.0) 65.5 (16.0) – –
a Statistical analyses were performed by using a parametric test (unpaired t test) when a normal distribution was present and when in order a non-parametric
test (Mann–Whitney U) to assess univariate significant associations between the stated continuous determinants and vitamin D deficiency. Categorical
determinants were analysed by using Pearson’s Chi-square test (or Fisher’s exact test when expected frequencies were low). All p values >0.10 are noted as
NS (non-significant). All p values between 0.5 and 0.10 are noted in order to evaluate non-significant trends associated with vitamin D deficiency
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products do not contain vitamin D2), and the intake of
dietary sources is minimal [17, 22]. The effects of dietary
intake of vitamin D are relatively poor in this study,
resulting in no significant effects of fatty fish intake in
summer or winter. Concerning lifestyle factors, the highly
significant positive effect of smoking on vitamin D levels is
remarkable. To our knowledge, no physiologic mechanism
exists which can explain this extraordinary association, and
these results may be caused by measurement interferences.
Recently, Grimnes et al. reported an overestimation of
25OHD levels in assays of smokers compared to non-
smokers measured with the ECLIA (Roche) method [23].
This phenomenon is caused by an up till now unknown
mechanism and should be evaluated by biochemical
Table 4 Patient characteristics stratified by vitamin D quartiles measured at the end of summer
25OHD quartiles, nmol/L p valuea
≤42 nmol/L 43–53 nmol/L 54–66 nmol/L ≥67 nmol/L
n=79 n=78 n=81 n=78
Ulcerative colitis, n (%) 39 (49.4) 46 (59.0) 53 (65.4) 47 (60.3) NS
Age, years (SD) 48.3 (14.3) 48.9 (14.9) 50.4 (15.7) 46.4 (14.3) NS
Women, n (%) 42 (53.2) 38 (48.7) 49 (60.5) 52 (66.7) NS
Postmenopausal state, n (% of women) 20 (47.6) 13 (34.2) 20 (40.8) 18 (34.6) NS
Body mass index, kg/m2 (SD) 26.2 (5.3) 26.3 (4.8) 24.5 (3.7) 24.0 (3.6) 0.010
Active IBD, n (%) 47 (59.5) 38 (48.7) 42 (51.9) 33 (42.3) NS
Disease duration IBD, years (SD) 11.3 (10.9) 10.4 (9.5) 12.2 (9.9) 10.2 (8.5) NS
Exacerbation IBD, episodes/year (SD) 2.9 (2.2) 2.8 (1.9) 2.7 (2.3) 2.6 (1.9) NS
History of >7.5 mg daily corticosteroid
usage for at least six months, n (%)
31 (39.2) 19 (24.4) 23 (28.4) 19 (24.4) NS
Daily use of oral vitamin D supplementation, n (%) 22 (27.8) 21 (26.9) 36 (44.4) 27 (34.6) 0.07
Low dietary calcium intake, n (%) 3 (3.8) 5 (6.4) 5 (6.2) 2 (2.6) NS
Fatty fish intake, units/month (SD) 2.2 (2.0) 3.4 (3.2) 2.6 (2.0) 2.4 (2.4) 0.05
Excessive alcohol usage, n (%) 6 (7.8) 8 (10.4) 10 (12.3) 10 (13.2) NS
Current smoking, n (%) 8 (10.1) 19 (24.4) 22 (27.2) 24 (30.8) 0.009
Preferred exposure to sun when outdoors, n (%) 29 (37.7) 43 (57.3) 38 (47.5) 56 (72.7) 0.003
Outdoor activities at least two hours a day, days/week (SD) 5.1 (2.3) 5.5 (1.9) 5.6 (2.1) 5.4 (2.3) NS
Sufficient physical activity, n (%) 66 (83.5) 73 (93.6) 68 (84.0) 73 (93.6) 0.06
Sun holiday in the last year, n (%) 26 (33.3) 23 (30.7) 40 (50.0) 49 (63.3) <0.001
Solarium visits, n (%) 9 (11.5) 13 (17.3) 18 (22.5) 24 (31.2) 0.020
Laboratory markers in serum
Hb, mmol/L (SD) 8.6 (1.0) 8.7 (0.9) 8.6 (1.0) 8.6 (0.8) NS
Ht, L/L (SD) 0.41 (0.04) 0.41 (0.03) 0.41 (0.04) 0.40 (0.03) NS
RDW, % (SD) 45.5 (5.5) 44.1 (4.8) 44.7 (4.5) 44.0 (3.9) NS
ESR, mm/h (SD) 16.3 (15.5) 14.3 (12.1) 13.9 (13.6) 12.0 (8.3) NS
CRP, mg/L (SD) 4.6 (5.7) 4.6 (7.5) 4.4 (10.5) 4.6 (6.3) NS
Calcium, mmol/L (SD) 2.4 (0.1) 2.3 (0.1) 2.4 (0.1) 2.3 (0.1) NS
Phosphate, mmol/L (SD) 1.1 (0.2) 1.1 (0.1) 1.1 (0.2) 1.1 (0.2) NS
Alkaline phosphatase, IU/L (SD) 79.1 (20.0) 82.4 (39.6) 71.4 (23.3) 74.9 (26.5) 0.022
Albumin, g/L (SD) 40.7 (3.2) 40.4 (3.3) 40.4 (3.2) 40.7 (3.3) NS
Creatinine, μmol/L (SD) 72.1 (15.4) 75.9 (15.7) 74.2 (17.2) 69.3 (13.6) 0.08
TSH, mIU/L (SD) 1.5 (0.8) 1.7 (1.0) 1.4 (0.6) 1.5 (0.9) NS
SD standard deviation, Hb haemoglobin, Ht haematocrit, RDW red blood cell distribution width, ESR erythrocyte sedimentation rate, CRP C-
reactive protein, TSH thyroid stimulating hormone
a Statistical analyses were performed by using one-way ANOVAwith a Bonferroni post hoc test as parametric test when a normal distribution was present
and when in order a non-parametric test (Kruskal–Wallis test) to assess univariate significant associations between the stated determinants and 25OHD
quartiles. All p values >0.10 are noted as NS (non-significant). All p values between 0.5 and 0.10 are noted in order to evaluate non-significant trends
associated with 25OHD quartiles
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measurement studies in the near future. Considering body
mass index, our results show, in accordance with previous
studies, a strong association between high body mass index
and low vitamin D levels [24]. This supports the hypothesis
that an increase of body mass index leads to a larger
distribution volume in the body for the fat-soluble vitamin
D which lowers the serum 25OHD concentration.
Vitamin D supplementation
In our study population, oral vitamin D supplementation is
significantly associated with a decreased risk of vitamin D
deficiency in summer (p = 0.029) and winter (p < 0.001).
Nevertheless, the effects of vitamin D supplementation are
far from satisfactory with the generally low dosages used in
this study, where daily intake does not exceed 200–400 IU/
day. At the end of summer, 30% of the patients using
supplementation were still vitamin D deficient. At the end
of winter, even 44% of the vitamin D supplemented
patients had serum 25OHD <50 nmol/L. The fact that only
a non-significant trend and not a significant relation could
be observed between higher dosages and serum 25OHD
levels is probably caused by the low dosages of vitamin D
supplementation in this study population. This year,
Jørgensen et al. published one of the first randomized
placebo-controlled trials among 108 CD patients to assess
Fig. 1 Mean serum 25OHD levels (nanomoles per litre) at the end of
summer and winter. Patients were classified as ‘vitamin D intake only
by ultraviolet (UV) light’ if they did not use oral vitamin D
supplementation and met one or two of the following criteria: regular
solarium visits and sun holiday in the last 6 months. Patients who used
oral supplementation without being exposed to ultraviolet light (no
solarium visits or sun holidays) were classified as ‘vitamin D intake
only by oral supplementation’. If patients used both oral supplemen-
tation and additional UV light, they were classified as ‘combined
vitamin D intake by UV light and oral supplementation’
Table 5 Odds ratios for potential determinants of vitamin D deficiency at the end of summer and winter
Odds ratio (95% CI)
Summera Winterb
Age 0.97 (0.95–1.00) 0.99 (0.97–1.01)
Female gender 0.59 (0.34–1.03) 0.78 (0.45–1.38)
Ulcerative colitis 0.55 (0.31–0.95) 0.91 (0.53–1.56)
Active IBD 1.50 (0.87–2.57) –c
Body mass index 1.11 (1.05–1.19) –c
Current smoking 0.27 (0.13–0.57) –c
Alkaline phosphatase 1.00 (0.99–1.01) –c
Preferred exposure to sun when outdoors 0.81 (0.47–1.41) –c
Oral vitamin D supplementation 0.52 (0.29–0.94) 0.44 (0.26–0.75)
Recent sun holiday 0.42 (0.24–0.74) 0.48 (0.20–1.14)
Regular solarium visits 0.28 (0.13–0.63) 0.17 (0.06–0.50)
Fatty fish intake 0.99 (0.89–1.10) 1.05 (0.93–1.18)
Outdoor activities at least 2 h a day 0.97 (0.86–1.10) 1.01 (0.91–1.13)
Analyses were done by using logistic regression with vitamin D deficiency (cut-off point, 50 nmol/L) in summer and winter as dependent
variables
a Summer model: adjusted for age, gender, type of IBD, disease activity of IBD, body mass index, current smoking, alkaline phosphatase, preferred
exposure to sun when outdoors, oral vitamin D supplementation during summer, recent sun holidays during summer, regular solarium visits during summer,
fatty fish intake during summer and outdoor activities during summer
bWinter model: adjusted for age, gender, type of IBD, oral vitamin D supplementation during winter, recent sun holidays during winter, regular solarium
visits during winter, fatty fish intake during winter and outdoor activities during winter
c Determinant not included in the logistic regression winter model
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the effects of 1,200 IU cholecalciferol daily on CD activity
[25]. The investigators concluded that these vitamin D
dosages decreased disease activity and, more importantly,
were safe to use. With regard to fracture risk reduction,
various meta-analyses reported a decrease of fracture risk of
13% to 26% with 700–800 IU vitamin D daily [26]. In
contrast to the general consensus, Sanders et al. recently
reported that one annual mega dosage of 600,000 IU
cholecalciferol caused an increase of falls and fractures
among 2,256 postmenopausal women [27]. Although the
biological mechanisms of these findings are unclear, they
indicate that the dosing regimen of cholecalciferol is
important, and infrequent extreme doses are counterpro-
ductive in decreasing fracture risk. Taking the existing
evidence into account, it is without doubt of major
importance to prevent bone fractures by vitamin D
supplementation which is frequently administered (i.e.
daily, weekly or monthly). Although the optimal vitamin
D supplementation dosages remain unclear, various authors
state that the currently prescribed dosages are generally too
low and can be raised up to 4,000 IU/day without any
adverse effects [25, 28–31]. Our results on vitamin D
supplementation support the need of further studies for
optimal vitamin D dosages in the general population and
specifically for the IBD subgroup.
Role of inflammatory process
The association in our study between vitamin D deficiency
and active IBD disease (including the increased haemato-
logical markers ESR and RDW), which was observed in
univariate analyses of the lowest and highest vitamin D
quartiles, is particularly interesting. Lately, RDW attracted
attention because of its potential correlation with immuno-
logic activity, which is interesting in chronic inflammatory
diseases. In line with our baseline results, which show a
significant higher RDW value in CD patients than in UC
patients, one pilot study reported that RDW has the ability
to differentiate between CD and UC [32]. Others proved
that high RDW values are significantly correlated to
alternated CRP and ESR levels showing that it can detect
inflammatory processes in the human body [33].
Interest in vitamin D increased after the identification of
vitamin D receptors (VDRs) in most tissues and cells in the
body and discovery of the importance of the active metabolite
(calcitriol) as a potent immunomodulator [22, 34]. Recently,
vitamin D deficiency was found to be associated with increased
incidences of cardiovascular disease, hypertension and cancer
[35–38]. Poor vitamin D status has already been linked to
auto-immune diseases like diabetes type 1, multiple sclerosis
and rheumatoid arthritis [39]. The association between IBD
activity and vitamin D has been described in animal studies
by some authors but is rarely reported in human studies [34,
40, 41]. Concerning CD patients, a new hypothesis states that
vitamin D deficiency is not only the consequence but also a
cause of the inflammatory process leading to bone loss
through a Th1-driven immune response [42]. This hypothesis
is recently supported by findings of an essential function of
VDR in the protection of the colonic mucosa by regulating
intestinal homeostasis in response to enteric bacterial invasion
and commensal bacterial colonization [43]. In addition, an
improvement of bone status and a decrease in IBD activity
after therapy with 1,25-dihydroxyvitamin D was described in
CD patients [44]. Although significant progression has been
made concerning the role of vitamin D and its receptor, the
exact mechanism is not yet fully understood and could lead to
a new breakthrough concerning the aetiology of IBD.
The above-mentioned results on disease activity and vitamin
D deficiency indicate that increased risk of osteoporosis in IBD
patients may not be caused by vitamin D deficiency only. In our
opinion, it is plausible that the inflammatory process itself
(which may be causally connected with vitamin D status in the
aetiology of IBD) might lead to a negative effect on bone status
through pro-inflammatory immunologic responses or a direct
action of interleukins on the osteoclast activity. This perspec-
tive is endorsed by Tilg et al., who suggested in a recent review
concerning the role of intestinal inflammation on bone health
that pro-inflammatory cytokines (TNFα, IL-1β, IL-6 and
interferon gamma (IFNγ)) which are involved in IBD not only
cause mucosal (or systemic) inflammation but might cause
bone loss as well [45].
Study limitations
A weakness in our study is that therapy compliance was
assessed without regularly monitoring 25OHD serum
levels. Although patients stated their supplementation usage
in a questionnaire, which was only seen by the researcher
and not by their own gastroenterologist, it is likely that
compliance is lower than declared. Therapy compliance of
vitamin D supplementation is more or less comparable with
bisphosphonate therapy because patients do not directly
notice the benefits of therapy. Poor therapy compliance of
bisphosphonate is recently described in a meta-analysis by
Imaz et al. showing that only 66% of the osteoporosis
patients possessed their prescribed medication after 1 year
of follow-up [46]. Whether low vitamin D levels despite
supplementation are caused by ineffective vitamin D
dosages, therapy compliance or other risk factors, the
present study shows that vitamin D supplementation is
suboptimal in IBD patients.
Furthermore, it is plausible that the correlation between
disease activity and the assessed inactive vitamin D
metabolites (25OHD) could be distorted by inflammatory
reactions influencing the 25OHD level without affecting the
function of the active 1,25-dihydroxyvitamin D metabolite.
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It is known that the circulation of 25OHD in serum depends
on proteins, such as the carrier vitamin binding protein (DBP),
of which concentrations may alter caused by pro- and anti-
inflammatory reactions. Nevertheless, in our view, it is rather
unlikely that DBP concentrations will drop beneath the
minimal concentration needed for 25OHD binding, due to
the fact that 25OHD uses only a small amount of the binding
sites of DBP available in the human body [47].
In conclusion, vitamin D deficiency is a common problem
as shown in this large sample of adults suffering from IBD.
Nevertheless, prevalence rates of vitamin D deficiency in IBD
patients might be comparable to the prevalence in the general
population. The importance of exposure to ultraviolet light for
an adequate vitamin D status is subscribed by the observed
seasonal variation of serum 25OHD levels between summer
and winter. At the end of winter, the number of patients with
vitamin D deficiency is increased by 50%. Preferred sun
exposure, sun holidays and solarium visits during
summer and winter were strongly associated with high
vitamin D levels. Factors associated with low vitamin D
levels are high disease activity of IBD, high body mass
index and increased haematological markers (ESR and RDW),
indicating that the increased risk of osteoporosis in IBD is
more related to the inflammatory process than to vitamin D
deficiency. The effects of oral vitamin D supplementation on
serum 25OHD are poor. Therefore, optimal vitamin D
supplementation dosages in IBD patients should be re-
evaluated in future studies.
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